TI
tirzepatide (Zepbound / MuFengDa / Mounjaro)
Eli Lilly ยท GIPR ยท Small Molecule
Status
โ Approved
Indications
11 conditions
Clinical Trials
188 total
Active Trials
125 ongoing
Targets
GIPR, GLP1R
What is tirzepatide?
Last updated: February 2025tirzepatide is a small molecule developed by Eli Lilly. It is approved for therapeutic indications via injectable (others) or subcutaneous injection.
Drug Profile
| Generic Name | tirzepatide |
| Brand Names | Zepbound, MuFengDa, Mounjaro |
| Company | Eli Lilly |
| Drug Class | Small Molecule, Polypeptide |
| Molecular Target | GIPR, GLP1R |
| Route | Injectable (Others), Subcutaneous Injection |
| Status | Approved |
Sources: ClinicalTrials.gov, Eli Lilly
Mechanism of Action
Molecular Targets
tirzepatide acts on 2 molecular targets:
| GIPR | gastric inhibitory polypeptide receptor (PGQTL2) |
| GLP1R | glucagon like peptide 1 receptor (GLP-1R, GLP-1-R) |
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.
Clinical Trials
There are currently 188 clinical trials registered, with 125 actively ongoing.
| Trial ID | Phase | Title | Status |
|---|---|---|---|
| NCT07349641 | Phase 2 | Tirzepatide With Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometr | โ Not Yet Recruiting |
| NCT06143956 | Phase 2 | A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Interventions for Chronic | โ Recruiting |
| NCT07165028 | Phase 3 | A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in A | โ Recruiting |
| NCT06937086 | Phase 3 | A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Conc | โ Recruiting |
| NCT06914895 | Phase 3 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluatin | โ Recruiting |
| NCT06939088 | Phase 2 | Effect of Tirzepatide on Alcohol Intake and Reward Processing in Patients Diagnosed With Schizophren | โ Recruiting |
+184 more trials available with free account
Sign up free to view all clinical trials โAnalyze Full Trial DataNoah can compare efficacy across trials and generate reports.
Therapeutic Indications
tirzepatide is developed for 11 unique indications across 7 therapeutic areas.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Metabolism and nutrition disorders | Obesity | โ Approved |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | โ Approved |
| Cardiac disorders | Cardiovascular disorder | โ Approved |
| Respiratory, thoracic and mediastinal disorders | Apnoea | โ Approved |
| Psychiatric disorders | Sleep disorder | โ Approved |
+6 more indications available with free account
Sign up free to view all indications โ